{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T02:33:49Z","timestamp":1794018829743,"version":"4.8.0"},"reference-count":51,"publisher":"Informa UK Limited","issue":"4","license":[{"start":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T00:00:00Z","timestamp":1740528000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Microbiology"],"published-print":{"date-parts":[[2025,3,4]]},"DOI":"10.1080\/17460913.2025.2468112","type":"journal-article","created":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T04:21:11Z","timestamp":1740543671000},"page":"277-286","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":49,"title":["Cefepime-enmetazobactam: first approved cefepime-\u03b2- lactamase inhibitor combination for multi-drug resistant Enterobacterales"],"prefix":"10.1080","volume":"20","author":[{"given":"Tanaya","family":"Bhowmick","sequence":"first","affiliation":[{"name":"1 Robert Wood Johnson Place","place":["New Brunswick, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Canton","sequence":"additional","affiliation":[{"name":"Instituto Ram\u00f3n y Cajal de Investigaci\u00f3n Sanitaria (IRYCIS)","place":["Madrid, Spain"]},{"name":"Instituto de Salud Carlos III","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Pea","sequence":"additional","affiliation":[{"name":"Alma Mater Studiorum, University of Bologna","place":["Bologna, Italy"]},{"name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","place":["Bologna, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Quevedo","sequence":"additional","affiliation":[{"name":"Advanz Pharma","place":["London, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Santerre Henriksen","sequence":"additional","affiliation":[{"name":"Maxel Consulting","place":["Jyllinge, Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fran\u00e7ois","family":"Timsit","sequence":"additional","affiliation":[{"name":"Assistance publique hopitaux de Paris \u2013 Bichat university hospital Medical and infectious diseases ICU","place":["Paris, France"]},{"name":"Universit\u00e9 Paris-Cit\u00e9, IAME, INSERM, F-75018","place":["Paris, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith S","family":"Kaye","sequence":"additional","affiliation":[{"name":"Rutgers Robert Wood Johnson Medical School","place":["New Brunswick, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,2,26]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.2717"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30747-8"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(19)30403-7"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa803"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30731-3"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S206966"},{"key":"e_1_3_4_9_1","unstructured":"Center for Disease Control and Prevention. Antimicrobial resistance & patient safety portal. Available from: https:\/\/arpsp.cdc.gov\/profile\/antibiotic-resistance?tab=antibiotic-resistance"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.33073\/pjm-2019-048"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12941-023-00638-3"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.12163"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlab092"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa399"},{"key":"e_1_3_4_15_1","unstructured":"Center for Disease Control and Prevention. Antimicrobial resistance threats in the United States 2021\u20132022. Available from: https:\/\/www.cdc.gov\/antimicrobial-resistance\/data-research\/threats\/update-2022.html"},{"key":"e_1_3_4_16_1","unstructured":"WHO. Bacterial priority pathogens list 2024: bacterial pathogens of public health importance to guide research development and strategies to prevent and control antimicrobial resistance. Geneva: World Health Organization; 2024. Available from: https:\/\/www.who.int\/publications\/i\/item\/9789240093461"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae403"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00327-19"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eimc.2018.03.003"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00607-13"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10156-007-0507-x"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1186\/cc9062"},{"key":"e_1_3_4_23_1","unstructured":"The U.S. Food and Drug Administration. FDA drug safety communication: FDA advises restricting fluoroquinolone antibiotic use for certain uncomplicated infections; warns about disabling side effects that can occur together. Available from: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-fda-advises-restricting-fluoroquinolone-antibiotic-use-certain"},{"key":"e_1_3_4_24_1","unstructured":"Medicines and Healthcare products Regulatory Agency. Fluoroquinolone antibiotics: must now only be prescribed when other commonly recommended antibiotics are inappropriate. Available from: https:\/\/www.gov.uk\/drug-safety-update\/fluoroquinolone-antibiotics-must-now-only-be-prescribed-when-other-commonly-recommended-antibiotics-are-inappropriate#:~:text=as%20a%20reminder%20of%20advice%20published%20in could%20exacerbate%20fluoroquinolone%2Dinduced%20tendinitis%20and%20te ndon%20rupture"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02569-17"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01970-17"},{"key":"e_1_3_4_27_1","unstructured":"The U.S. Food and Drug Administration Prescribing information Exblifep. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/216165s000lbl.pdf"},{"key":"e_1_3_4_28_1","unstructured":"The European medicines agency summary of product characteristics exblifep. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/exblifep-epar-product-information_en.pdf"},{"key":"e_1_3_4_29_1","unstructured":"Medicines & healthcare products regulatory agency summary of product characteristics exblifep. Available from: https:\/\/mhraproducts4853.blob.core.windows.net\/docs\/cac3157dcca7a86e2547920f4a0ea399d7d51bc1"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1586\/14787210.6.6.805"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(07)70109-3"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00105-19"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2021.02.031"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00514-19"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2024.04.014"},{"key":"e_1_3_4_36_1","article-title":"Breakpoint tables for interpretation of MICs and zone diameters","volume":"15","author":"The European Committee on Antimicrobial Susceptibility Testing","year":"2025","unstructured":"The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version. 2025; 15. Available from: http:\/\/www.eucast.org","journal-title":"Version"},{"key":"e_1_3_4_37_1","unstructured":"The U.S. Food and Drug Administration. Fda-recognized antimicrobial susceptibility test interpretive criteria Cefepime and enmetazobactam injection. Available from: https:\/\/www.fda.gov\/drugs\/development-resources\/cefepime-and-enmetazobactam-injection"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2024.09.031"},{"key":"e_1_3_4_39_1","volume-title":"Poster presented at the ESCMID Global conference","author":"Delgado Valverde M","year":"2024","unstructured":"Delgado Valverde M, Perez Palacios P, Fernandez Cuenca F, et al. Activity of cefepime\/enmetazobactam, a new betalactam\/betalactamase inhibitor combination, against multidrug-resistant Enterobacterales and Acinetobacter baumannii. In: Poster presented at the ESCMID Global conference; Barcelona, Spain; 2024 Apr 27\u201330."},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2024.2427310"},{"key":"e_1_3_4_41_1","unstructured":"The U.S. Food and Drug Administration. Center for drug evaluation and research integrated review exblifep 2024. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2024\/216165Orig1s000IntegratedR.pdf"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00078-20"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.02345-24"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00180-20"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01468-20"},{"key":"e_1_3_4_46_1","volume-title":"Poster presented at the ESCMID Global conference","author":"Vollmer J","year":"2024","unstructured":"Vollmer J, Machacek M, Dunkel N, et al. Cefepime\/Enmetazobactam dose adjustments for renal function in patients using population pharmacokinetic simulations. In: Poster presented at the ESCMID Global conference; Barcelona, Spain; 2024 Apr 27\u201330."},{"key":"e_1_3_4_47_1","volume-title":"Poster 02214, presented at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID)","author":"Quevedo J","year":"2023","unstructured":"Quevedo J, Dunkel N, Belley A, et al. Probability of target attainment of cefepime\/enmetazobactam in patients with complicated urinary tract infections or acute pyelonephritis. In: Poster 02214, presented at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID); Copenhagen, Denmark; 2023 Apr 15\u201318."},{"key":"e_1_3_4_48_1","volume-title":"Poster presented at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID)","author":"Quevedo J","year":"2023","unstructured":"Quevedo J, Dunkel N. Belley A, et al. Probability of target attainment of cefepime\/enmetazobactam to support dose selection for the treatment of pulmonary infections. In: Poster presented at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID); Copenhagen, Denmark; 2023 Apr 15\u201318."},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41429-022-00592-w"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.17034"},{"key":"e_1_3_4_51_1","unstructured":"The European Medicines Agency. Public assessment report 2024. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/exblifep-epar-public-assessment-report_en.pdf"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.CCM.0000069734.38738.C8"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-017-1856-1"}],"container-title":["Future Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17460913.2025.2468112","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T14:20:14Z","timestamp":1762957214000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17460913.2025.2468112"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,26]]},"references-count":51,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,3,4]]}},"alternative-id":["10.1080\/17460913.2025.2468112"],"URL":"https:\/\/doi.org\/10.1080\/17460913.2025.2468112","relation":{},"ISSN":["1746-0913","1746-0921"],"issn-type":[{"value":"1746-0913","type":"print"},{"value":"1746-0921","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,26]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifmb20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifmb20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-12-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}